Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe
Interview with the Innovators

Interview with the Innovators

Identification of new actionable targets and driver mutations have revolutionized the treatment of NSCLC
Waiting for biomarker test results ensures the best outcomes in NSCLC.
Describing the road map of the cancer care journey in NSCLC.
Nephrectomy is often the initial treatment for renal-cell cancer (RCC), but systemic therapy is frequently required for advanced RCC. Single-agent targeted therapies are only somewhat effective, which led to the development of immunotherapies and combination therapies (which include immunotherapies). Laura Wood, RN, MSN, OCN, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss the clinical advantages of combination therapies in patients with advanced RCC.
Laura Wood, RN, MSN, OCN, Megan Price, MSN, APRN, FNP-C, and Virginia Seery, MSN, RN, ANP-BC, AOCNP, discuss their roles and responsibilities within their academic oncology centers as valuable members of a multidisciplinary team that helps patients successfully navigate the spectrum of patient care. They also detail how they apply the principles of patient-centered care to improve outcomes for patients.
The use of targeted agents and immunotherapy has transformed the treatment of NSCLC
Encouraging shared decision making by NSCLC by educating and counseling patients and their families
Reflex NGS testing is now the standard of care for many patients with NSCLC
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, provide their support for the use of PARP inhibitors as maintenance therapy in ovarian cancer, and that the optimization of this therapy requires further research to discover the best therapeutic combinations that will be personalized based on patient characteristics.
Amina Ahmed, MD, Paula Anastasia, RN, MN, AOCN, and Ali McBride, PharmD, MS, consider the current and future use of immunotherapy, either alone or in combination with other agents such as PARP inhibitors, as first-line maintenance therapy in ovarian cancer.
Page 1 of 3
Results 1 - 10 of 23